About
Virax Biolabs Group Limited is a biotechnology company based in Lanarkshire, United Kingdom, founded in 2013. The company specializes in developing and distributing diagnostic test kits aimed at the prevention, detection, diagnosis, and management of viral diseases through T cell in vitro diagnostics. Virax offers a range of products under various brands. ViraxClear provides in-vitro diagnostic test kits for respiratory diseases, pregnancy, infectious diseases, and more. ViraxVet focuses on rapid and molecular tests for small animal veterinary diagnostics. The ViraxImmune™ platform includes a T cell diagnostic device and a wellness mobile application, along with tools for immune profiling and cytokine detection. In addition to its product offerings, Virax Biolabs provides services such as antibody engineering, custom peptide synthesis, and vaccine efficacy testing. The company serves a diverse clientele, including research organizations, hospitals, and laboratories across the UK, US, and China. Virax Biolabs went public on July 21, 2022, and is committed to advancing global health through innovative immunology solutions.
Technologies
Keywords
Company Information
-
Employees 17
-
Founded 2013
-
Annual Revenue $6000
-
Total Funding $19550000
Location
30 Broadwick Street, London, England, United Kingdom, W1F 8JB
